Hengrui and GSK Collaborate on $12 Billion COPD and Drug Development Deal
Jiangsu Hengrui Pharmaceuticals shares surged after GSK agreed to pay up to $12 billion in a licensing deal for multiple drug candidates, including a potential COPD treatment, marking the largest deal for Chinese drug innovators and highlighting the growing international recognition of Chinese pharmaceutical innovations.